Dr. Mathieu Gauthé, MD, PhD, Habilitation, is a senior physican specialized in nuclear medicine. Since 2012, he is working on molecular imaging in oncology, especialy radiotracers which are used for PET/CT imaging and radioligand therapy. His research activities are focused on the medico-economic optimization of the use of those radiotracers in oncology. In 2016, he contributed to the developement and use of PSMA-ligands radiotracers for imaging and treatment of prostate cancer in France. He is an active member of the Oncology Commitee of the French Urological Society.